Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program

Reuters

11/05

Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program

Centessa Pharmaceuticals plc reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569016-en) on November 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581292727"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581292727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581292727?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581292727","market":"fut","top_or_hot":-1,"title":"Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569016-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals reports Q3 results and updates OX2R agonist program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569016-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL9P544Q:1","article_id":"2581292727","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581292727","pubTimestamp":1762344079,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Centessa Pharmaceuticals plc reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4539":"次新股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4535":"淡马锡持仓","CNTA":"Centessa Pharmaceuticals plc","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Centessa Pharmaceuticals报告第三季度业绩并更新OX2R激动剂计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9,"NDAQ":0.9},"content_text":"Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program\n    \n\nCentessa Pharmaceuticals plc reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569016-en) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}